Business
Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology
-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the U.S. -- -- Highly Complementary Business
About this update from Hamilton Lane Incorporated
[{"type":"text","content":"\n-- Acquisition Propels Cosette Into One Of The Leading Companies In Women’s Health and Dermatology in the U.S. --\n\n-- Highly Complementary Business Strengthens Cosette’s Portfolio, Commercial and Manufacturing Footprint and Expands Geographic Reach --\n\n-- Utilizing Mayne Pharma’s Impressive Commercial and Sales Track Record to Drive Further Growth and Enhanced Patient Access --\n\n BRIDGEWATER, N.J.--(BUSINESS WIRE)--\nCosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recommended that its shareholders vote in favor of the transaction. The transaction is expected to close in the second quarter of 2025.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220569463/en/(Photo: Business Wire)\n“This acquisition marks a transformational step for Cosette, adding patented, high-growth products to solidify our leadership in women’s health in the U.S. and expanding our reach globally,” said Apurva Saraf, President and CEO of Cosette Pharma. “By combining Cosette’s strong portfolio with Mayne Pharma’s proven commercial expertise, the combined company will be well positioned to further invest in innovation, portfolio expansion and better serve our patients. We look forward to a timely closing and welcoming Mayne Pharma to the Cosette family.”\n\n“Joining the Cosette team amplifies our shared mission to improve lives through innovative and accessible Women’s health and dermatology medicines,” said Shawn Patrick O’Brien, CEO, Mayne Pharma. “This transaction represents a unique opportunity for our employees, customers, and patients. Together, we will extend the reach of important therapies, drive innovation, and improve patient access.”\n\nTransaction Rationale\n\n\nStrengthens Cosette’s dermatology and women’s health businesses\nThe combination will create a leading women’s health and dermatology focused pharmaceuticals company in the U.S. with an established presence in intern...